{"id":44672,"date":"2022-06-03T17:01:49","date_gmt":"2022-06-03T15:01:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lateral-flow-immunoassay-lfia-based-rapid-test-global-market-research-report-2022-researchandmarkets-com\/"},"modified":"2022-06-03T17:01:49","modified_gmt":"2022-06-03T15:01:49","slug":"lateral-flow-immunoassay-lfia-based-rapid-test-global-market-research-report-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lateral-flow-immunoassay-lfia-based-rapid-test-global-market-research-report-2022-researchandmarkets-com\/","title":{"rendered":"Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Research Report 2022 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2022”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global lateral flow immunoassay (lfia) based rapid test market is expected to grow from $6.08 billion in 2021 to $6.66 billion in 2022 at a compound annual growth rate (CAGR) of 9.4%. The market is expected to grow to $9.08 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%.\n<\/p>\n

\nMajor players in the lateral flow immunoassay (LFIA) based rapid test market are Abbott Laboratories, F. Hoffmann-La Roche, Danaher Corporation, Siemens AG, Becton, Dickinson and Company, bioMerieux, Bio-Rad Laboratories, Thermo Fisher Scientific, QIAGEN NV, and Hologic Inc.\n<\/p>\n

\nThe lateral flow immunoassay (LFIA) based rapid test market consists of sales of devices and equipment used to run lateral flow immunoassays (LFIA) based rapid test and related services by companies that develop lateral flow immunoassays (LFIA) based rapid test equipment. These are testing devices used to assess the existence of a target, such as pathogens or biomarkers, in samples obtained from the human body or animals, or pollutants in water sources, food, or animal feed.\n<\/p>\n

\nThe main techniques in lateral flow immunoassay-based rapid test are competitive assay, sandwich assay, and multiplex detection assay. The competitive assay is used to assess the existence of a target, such as pathogens or biomarkers in the samples. The applications are infectious disease, pregnancy and fertility, toxicology, others that are used in hospitals and clinics, diagnostic laboratory, home care, and others.\n<\/p>\n

\nNorth America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2021. Asia Pacific was the second largest region in the lateral flow immunoassay (LFIA) based rapid test market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.\n<\/p>\n

\nThe demand for point-of-care testing under home care settings is expected to drive the Lateral Flow Immunoassay (LFIA) Based Rapid Test market. Point-of-care (POCT) testing is essential for rapid on-site diagnosis and treatment. The most important features for current POCT diagnostic systems are a quick analysis time with a test-to-answer format.\n<\/p>\n

\nLateral flow immunoassays (LFIA) are widely used as POCTs due to their speed and precision, simplicity, and low cost. For instance, the recent outbreak of coronavirus disease (COVID-19) has increased the significance of these devices to rapid screening and surveillance.\n<\/p>\n

\nAcro Biotech COVID-19 Rapid POC CE-IVD is a lateral flow immunoassay that quantifiably assesses the existence of patient-generated IgG and IgM antibodies to SARS-CoV-2, the causative agent of novel coronaviral disease COVID-19. These antibodies may be detected in whole blood, serum, or plasma samples in the test cassette. OZO has developed three different variations of its products using the Latex Enhanced Lateral Flow Immunoassays (LFIAs) method for testing COVID-19. Therefore, the need for point-of-care testing under home care settings is expected to drive the Lateral Flow Immunoassay (LFIA) Based Rapid Test market.\n<\/p>\n

\nLow sensitivity of Lateral Flow Immunoassay (LFIA) Based Rapid Test is expected to limit the market. The sensitivity of the test is mainly the ability of the test to correctly identify those with the disease, which is low for Lateral Flow Immunoassay (LFIA) Based Rapid Test compared to other methods that may, in some cases, require a re-test for confirmation. according to a study conducted by researchers, including those from the Harvard medical school in the USA and also the University of British Columbia, Canada.\n<\/p>\n

\nThe medical databases and preprint servers were searched from January 1 to April 30, 2020, for studies measuring the sensitivity and specificity of the COVID-19 antibody test compared to the control test. It had been found that pooled sensitivities were consistently lower for the lateral flow immunoassay (LFIA) test compared to other test methods. The low level of sensitivity is anticipated to restrain the market growth for Lateral Flow Immunoassay (LFIA) based rapid test.\n<\/p>\n

\nCompanies are collaborating to launch new products. In May 2020, Lateral Flow Diagnostic Company Mologic Ltd., which has teamed up with Biosure Ltd., the developer of the only CE-approved HIV home testing kit, to develop a COVID-19 antibody self-test. The companies combine Mologic’s validated IgG lateral flow test strip with Biosure’s test kit.\n<\/p>\n

\nIn July 2020, MP Biomedicals Asia Pacific Pte Ltd collaborated with a Singapore company A*STAR to create the ASSURE SARS-CoV-2 IgG \/ IgM rapid antibody test kit to detect IgG and IgM antibodies in a person infected with SARS-CoV-2. The kit delivers precise results in very less time as less as 15 minutes and uses the lateral flow method.\n<\/p>\n

\nIn April 2020, True Diagnostics, a leading US-based Point of Care (POC) company, partnered with Veravas and Infectolab Americas to create and distribute a fast, point-of-care immunoassay for SARS-CoV-2, the VeraTest SARS-CoV-2 IgA \/ IgG Fast Test will be developed to detect immunoglobulin A and immunoglobulin G antibodies to SARS-CoV-2 in the blood within 15 minutes.\n<\/p>\n

\nThe test combines True Diagnostics, TrueDx lateral flow immunoassay technology with Veravas, VeraPrep clean, and VeraPrep capture technologies designed to remove cross-reaction antibodies and ensure the detection of only SARS-CoV-2-specific antibodies. Veravas is an emerging US-based diagnostic company. Infectolab Americas is a US-based laboratory specialized in lab testing for tick-borne disease.\n<\/p>\n

\nKey Topics Covered:<\/strong>\n<\/p>\n

\n1. Executive Summary<\/strong>\n<\/p>\n

\n2. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Characteristics<\/strong>\n<\/p>\n

\n3. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Trends And Strategies<\/strong>\n<\/p>\n

\n4. Impact Of COVID-19 On Lateral Flow Immunoassay (LFIA) Based Rapid Test<\/strong>\n<\/p>\n

\n5. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Size And Growth<\/strong>\n<\/p>\n

\n5.1. Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Historic Market, 2016-2021, $ Billion\n<\/p>\n

\n5.1.1. Drivers Of The Market\n<\/p>\n

\n5.1.2. Restraints On The Market\n<\/p>\n

\n5.2. Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Forecast Market, 2021-2026F, 2031F, $ Billion\n<\/p>\n

\n5.2.1. Drivers Of The Market\n<\/p>\n

\n5.2.2. Restraints On the Market\n<\/p>\n

\n6. Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Segmentation<\/strong>\n<\/p>\n

\n6.1. Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Market, Segmentation By Technique, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion\n<\/p>\n